Alpha-1-antichymotrypsin as a novel biomarker for diagnosis, prognosis, and therapy prediction in human diseases

Jin, Yifei; Wang, Weidong; Wang, Qiyun; Zhang, Yueyang; Zahid, Kashif Rafiq; Raza, Umar; Gong, Yongsheng

doi:10.1186/s12935-022-02572-4

Cited by 28 publications

(24 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The glycoprotein AACT is a serine protease inhibitor involved in the acute phase response and proteolysis (UniProtKB). Its dysregulation and glycosylation levels are associated with tumor progression and recurrence [ 40 ]. A1BG, another glycoprotein belonging to the immunoglobulin superfamily, was found overexpressed by proteomics in various forms of cancer, such as pancreatic ductal adenocarcinoma [ 41 ], cervical intraepithelial neoplasia [ 42 ] and bladder cancer [ 43 ].…”

Section: Discussionmentioning

confidence: 99%

“…Additionally, A1BG has been found to be associated with tumor heterogeneity and malignancy in an animal model of breast cancer [ 44 ]. Recently, its key role in tumorigenesis has been confirmed, suggesting that A1BG could be a promising target for cancer diagnosis, prognosis, and therapy [ 40 ]. Regarding A1AT, its high levels have been positively correlated with unfavorable clinical outcomes in cancer [ 45 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Research of Prostate Cancer Urinary Diagnostic Biomarkers by Proteomics: The Noteworthy Influence of Inflammation

et al. 2023

View full text Add to dashboard Cite

Nowadays, in the case of suspected prostate cancer (PCa), tissue needle biopsy remains the benchmark for diagnosis despite its invasiveness and poor tolerability, as serum prostate-specific antigen (PSA) is limited by low specificity. The aim of this proteomic study was to identify new diagnostic biomarkers in urine, an easily and non-invasively available sample, able to selectively discriminate cancer from benign prostatic hyperplasia (BPH), evaluating whether the presence of inflammation may be a confounding parameter. The analysis was performed by two-dimensional gel electrophoresis (2-DE), mass spectrometry (LC-MS/MS) and Enzyme-Linked Immunosorbent Assay (ELISA) on urine samples from PCa and BPH patients, divided into subgroups based on the presence or absence of inflammation. Significant quantitative and qualitative differences were found in the urinary proteomic profile of PCa and BPH groups. Of the nine differentially expressed proteins, only five can properly be considered potential biomarkers of PCa able to discriminate the two diseases, as they were not affected by the inflammatory process. Therefore, the proteomic research of novel and reliable urinary biomarkers of PCa should be conducted considering the presence of inflammation as a realistic interfering element, as it could hinder the detection of important protein targets.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Research of Prostate Cancer Urinary Diagnostic Biomarkers by Proteomics: The Noteworthy Influence of Inflammation

et al. 2023

View full text Add to dashboard Cite

show abstract

“…A1AG2 (orosomucoid) was upregulated in idiopathic nephrotic syndrome and diabetic nephropathy and associated with disease progression [ 29 , 30 , 31 ]. AACT, a serine protease inhibitor, also termed SerpinA3, is mainly synthesized in the liver and protects against different inflammatory diseases [ 32 ]. Urinary AACT levels were positively correlated with preclinical renal fibrosis following AKI [ 33 ].…”

Section: Discussionmentioning

confidence: 99%

Urinary Protein Profiling for Potential Biomarkers of Chronic Kidney Disease: A Pilot Study

et al. 2022

View full text Add to dashboard Cite

Proteinuria is a risk factor for chronic kidney disease (CKD) progression and associated complications. However, there is insufficient information on individual protein components in urine and the severity of CKD. We aimed to investigate urinary proteomics and its association with proteinuria and kidney function in early-stage CKD and in healthy individuals. A 24 h urine sample of 42 individuals (21-CKD and 21-healthy individuals) was used for mass spectrometry-based proteomics analysis. An exponentially modified protein abundance index (emPAI) was calculated for each protein. Data were analyzed by Mascot software using the SwissProt database and bioinformatics tools. Overall, 298 unique proteins were identified in the cohort; of them, 250 proteins belong to the control group with median (IQR) emPAI 39.1 (19–53) and 142 proteins belong to the CKD group with median (IQR) emPAI 67.8 (49–117). The level of 24 h proteinuria positively correlated with emPAI (r = 0.390, p = 0.011). The emPAI of some urinary proteomics had close positive (ALBU, ZA2G, IGKC) and negative (OSTP, CD59, UROM, KNG1, RNAS1, CD44, AMBP) correlations (r < 0.419, p < 0.001) with 24 h proteinuria levels. Additionally, a few proteins (VTDB, AACT, A1AG2, VTNC, and CD44) significantly correlated with kidney function. In this proteomics study, several urinary proteins correlated with proteinuria and kidney function. Pathway analysis identified subpathways potentially related to early proteinuric CKD, allowing the design of prospective studies that explore their response to therapy and their relationship to long-term outcomes.

show abstract

“…But deficiency of ACT relates to liver disease, and in the case of BC, it is a prognostic favorable marker. Decreased ACT level was associated with poor survival in patients with liver cancer, increased ACT level was associated with shorter survival in patients with PDAC, and decreased ACT expression was associated with shorter survival in patients with early lung cancer [63]. Based on quantitative proteomics data it was suggested that the GlcNAcylated ACT will be a promising clinical biomarker in the diagnosis of early NSCLC [64].…”

Section: Alpha-1-antichymotrypsin (Aact_human)mentioning

confidence: 99%

Construction of 2DE-Patterns of Plasma Proteins: Aspect of Potential Tumor Markers

Naryzhny¹,

Ронжина²,

Zorina³

et al. 2022

Preprint

View full text Add to dashboard Cite

Cancer is a complex systemic disease that changes the entire proteome. The analysis of this transformation makes it possible to determine tumor markers, that is, the most characteristic biomacromolecules produced by tumor cells. Here, the question of finding ideal tumor markers, which should be sensitive, specific, and reliable, is an acute issue. Unfortunately, none of the tumor markers, even those used in the clinic, has all these characteristics. Despite this, many tumor markers have demonstrated excellent clinical relevance for monitoring the effectiveness of different treatments for cancer patients. The use of markers also aids in the early detection of cancer recurrence and prognosis. Therefore, the situation in this area can be improved in two ways – by attempting to find an ideal single tumor marker or generating panels of different markers. In both cases, proteomics certainly plays a major role. Human plasma is one of the most popular samples as it is commonly collected in the clinic and provides noninvasive, rapid analysis for any type of disease including cancer. Many efforts have been applied in searching for “ideal” tumor markers digging very deep plasma proteome. There is a line of evidence that the most abundant, so-called “classical plasma proteins”, may be used to generate a tumor biomarker profile. To be comprehensive these profiles should have information not only about protein levels but proteoform distribution for each protein. Initially, the profile of these proteins in norm should be generated. Here, we present data about these profiles generated by two-dimensional electrophoresis with the following mass-spectrometry and immunodetection.

show abstract

Alpha-1-antichymotrypsin as a novel biomarker for diagnosis, prognosis, and therapy prediction in human diseases

Cited by 28 publications

References 77 publications

Research of Prostate Cancer Urinary Diagnostic Biomarkers by Proteomics: The Noteworthy Influence of Inflammation

Research of Prostate Cancer Urinary Diagnostic Biomarkers by Proteomics: The Noteworthy Influence of Inflammation

Urinary Protein Profiling for Potential Biomarkers of Chronic Kidney Disease: A Pilot Study

Construction of 2DE-Patterns of Plasma Proteins: Aspect of Potential Tumor Markers

Contact Info

Product

Resources

About